Tüzün Y, Kotogyan A, Oguz O
Department of Dermatology, Cerrahpasa Faculty of Medicine, Istanbul, Turkey.
Int J Dermatol. 1992 Oct;31(10):720-1. doi: 10.1111/j.1365-4362.1992.tb01382.x.
A double-blind study with terbinafine was performed in 39 patients with dermatophyte infection, between 1987 and 1989, to compare the safety and efficacy of two dosage schedules of 125 mg twice daily versus 250 mg once daily. Mycologic assessments were negative by microscopic examination and Sabouraud's culture in 59% and 100% of patients in the first and the fourth weeks of treatment, respectively. There was no statistically significant difference between the two groups of patients receiving 125 mg b.i.d. and 250 mg q.d. with respect to the safety and efficacy of the treatment; however, the differences between the sums of clinical scores before and after the treatment were statistically significant. There were no adverse effects, and the drug was well tolerated.
1987年至1989年期间，对39例皮肤癣菌感染患者进行了一项关于特比萘芬的双盲研究，以比较每日两次125毫克与每日一次250毫克两种给药方案的安全性和疗效。在治疗的第一周和第四周，分别有59%和100%的患者经显微镜检查和沙氏培养真菌学评估为阴性。接受每日两次125毫克和每日一次250毫克治疗的两组患者在治疗安全性和疗效方面无统计学显著差异；然而，治疗前后临床评分总和的差异具有统计学意义。未出现不良反应，药物耐受性良好。
